(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 41.83% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Autolus Therapeutics's revenue in 2026 is $117,390,000.On average, 12 Wall Street analysts forecast AUTL's revenue for 2026 to be $35,032,313,515, with the lowest AUTL revenue forecast at $31,745,206,146, and the highest AUTL revenue forecast at $41,082,188,049. On average, 12 Wall Street analysts forecast AUTL's revenue for 2027 to be $57,930,276,831, with the lowest AUTL revenue forecast at $39,125,893,380, and the highest AUTL revenue forecast at $77,413,374,759.
In 2028, AUTL is forecast to generate $91,357,630,230 in revenue, with the lowest revenue forecast at $52,921,097,828 and the highest revenue forecast at $116,818,738,806.